Exhibit 99.1 ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held a ...

Core Insights - Royalty Pharma expects Portfolio Receipts for 2024 to reach approximately $2.8 billion, reflecting a year-over-year growth of about 13% in Royalty Receipts [2][3][7] - The company has deployed around $2.8 billion in capital for royalty transactions in 2024, marking a record year for synthetic royalty deals [2][5] - Royalty Pharma's development-stage pipeline has the potential to generate over $1 billion in new royalties from innovative therapies across various therapeutic categories [2][8] Financial Performance - Preliminary unaudited results indicate that Royalty Pharma anticipates adjusted EBITDA for 2024 to be between $2,560 million and $2,570 million, with Portfolio Cash Flow expected to be approximately $2,450 million to $2,455 million [3][26] - Net cash provided by operating activities is projected to be around $2,760 million to $2,770 million for the full year 2024 [3][26] Capital Deployment and Pipeline - Since 2020, Royalty Pharma has announced transactions totaling approximately $15.5 billion, with significant additions in 2024 including royalties on Voranigo and frexalimab [5][8] - The company is set to benefit from several new product launches in 2025, including Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy [6][7] Upcoming Events - Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 6:45 p.m. ET [9]

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intend ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intend ...

Group 1: W.P. Carey - W.P. Carey is a real estate investment trust (REIT) trading approximately 35% below its 2022 peak, currently offering a 6.2% yield [3][5] - The REIT has a 98.8% occupancy rate after spinning off 59 buildings into another company, which has allowed it to focus on its remaining properties [3][6] - W.P. Carey has raised its dividend payout three times since the spinoff and expects adjusted funds from operations to be between $4.65 and $4.71 per share this year, significantly above its current dividend obligation of $3.50 annually [5][6] - The REIT owns 1,430 single-tenant buildings across Europe and North America, with a well-diversified tenant list [6][7] Group 2: Royalty Pharma - Royalty Pharma offers a 3.2% yield and invests in drugmakers in exchange for royalty stakes in their products, benefiting from the reliable trend of increasing prescription drug expenses [8][9] - The company has a stake in 15 blockbuster drugs generating over $1 billion in annual sales and has raised its dividend four times since going public in 2020, totaling a 40% increase [9][10] - Royalty Pharma has announced transactions worth $10.1 billion since the start of 2022, with expectations for significant earnings growth in the coming years [10][11] - The company is positioned to capitalize on the need for over $1 trillion in capital for startup drugmakers over the next decade, making it a leading provider of royalty financing [11]

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize i ...

Royalty Pharma (RPRX) reported $735 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 15.4%. EPS of $1.04 for the same period compares to $0.79 a year ago.The reported revenue represents a surprise of +3.39% over the Zacks Consensus Estimate of $710.89 million. With the consensus EPS estimate being $0.95, the EPS surprise was +9.47%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to det ...

Financial Data and Key Metrics Changes - Royalty Pharma reported a 15% growth in Portfolio Receipts and Royalty Receipts in Q3 2024, driven by a high-quality portfolio of over 35 commercial products [8][11] - The company raised its full-year 2024 guidance for Portfolio Receipts to a range of $2.75 billion to $2.8 billion, reflecting expected growth in Royalty Receipts of around 11% to 13% [11][39] - Year-to-date capital deployment reached approximately $2.6 billion, with $95 million spent on share repurchases in the quarter [9][30] Business Line Data and Key Metrics Changes - The cystic fibrosis franchise, Trelegy, and Tremfya were highlighted as key growth drivers for Royalty Receipts [26] - Recent acquisitions included royalties on three novel therapies, with significant potential for growth from FDA approvals of Cobenfy, Voranigo, and Tremfya [10] Market Data and Key Metrics Changes - The company noted a strong performance in the chronic graft versus host disease (GVHD) market, with the acquisition of a synthetic royalty on Niktimvo, expected to launch in early 2025 [14][15] - The market for synthetic royalties is anticipated to grow, with Royalty Pharma achieving $800 million in synthetic royalty transactions in 2024 alone [25] Company Strategy and Development Direction - Royalty Pharma continues to focus on acquiring new royalties and maintaining a robust pipeline, emphasizing a balanced capital allocation strategy [9][35] - The company aims to deploy $10 billion to $12 billion in value-enhancing royalty acquisitions over a five-year period, with a strong track record of capital deployment [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver double-digit growth consistently, citing a diversified portfolio as a key strength [58] - The company remains optimistic about the future, with expectations for continued strong performance driven by recent acquisitions and market opportunities [44][46] Other Important Information - Royalty Pharma maintains significant financial capacity for future acquisitions, with approximately $3 billion available through cash and access to debt markets [31][32] - The company has a weighted average cost of debt of 3.1% and a leverage ratio of around 3x total debt to adjusted EBITDA [32][33] Q&A Session Summary Question: Insights on Cobenfy/KarXT label - Management expressed satisfaction with the Cobenfy approval and its potential to address unmet patient needs in schizophrenia [48][50] Question: Impact of CF business on urgency for new deals - Management indicated that while the cystic fibrosis business has moderated, it still expects growth and does not change the urgency for new investments [52][54] Question: Timeline for Niktimvo market penetration - Management is optimistic about Niktimvo's launch and market penetration, citing significant unmet patient needs [66] Question: High-level thoughts on 2025 guidance - Management refrained from providing specific guidance for 2025 but expressed confidence in the current portfolio and growth opportunities [70] Question: Competitive landscape for Cobenfy - Management acknowledged the potential competition from AbbVie's emraclidine but viewed it as a positive for the market overall [78] Question: Adoption challenges for Niktimvo due to IV administration - Management believes that despite Niktimvo being IV administered, the significant unmet need will drive its adoption [90]

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q3 2024 Financial Results November 6, 2024 2 Forward Looking Statements & Non-GAAP Measures This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the d ...

Exhibit 99.1 1 ROYALTY PHARMA REPORTS THIRD QUARTER 2024 RESULTS • Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15% • Net cash provided by operating activities of $704 million • Capital Deployment of approximately $1.2 billion • Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, NY, November 6, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 gui ...